Enhancing Circular RNA Translation Efficiency Through Dual Internal Ribosome Entry Sites
Simple Summary
Abstract
1. Introduction
2. Materials and Methods
2.1. Sample Preparation
2.1.1. Molecular Cloning
2.1.2. Generation of dsDNA Templates
2.1.3. RNA Preparation
2.2. Cell Culture and Transfection
2.3. In Vitro NanoLuc Assay
2.4. Microscope Imaging
2.5. Quantification of EGFP Expression
3. Results
3.1. Construction and Preparation of Circular RNAs with Single or Dual IRES Elements
3.2. Screening of Synergistically Functional Dual-IRES Combinations
3.3. The Optimized Dual IRES Configuration Achieves Maximal Nanoluc Efficiency
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
Abbreviations
| circRNA | circular RNA |
| PIE | permuted intron-exon |
| IRES | internal ribosome entry sites |
| CDS | coding sequence |
| UTR | untranslated region |
| EMCV | Encephalomyocarditis virus |
| CVB3 | Coxsackievirus B3 |
| EV-A71 | Enterovirus A71 |
| HRV | Human Rhinovirus |
| iEV-B107 | Enterovirus B107 |
| ITAFs | internal ribosome entry site trans-acting factors |
| PTB | polypyrimidine tract-binding protein |
| PCBP2 | poly(rC)-binding protein 2 |
References
- Krammer, F. SARS-CoV-2 vaccines in development. Nature 2020, 586, 516–527. [Google Scholar] [CrossRef] [PubMed]
- Qin, S.; Tang, X.; Chen, Y.; Chen, K.; Fan, N.; Xiao, W.; Zheng, Q.; Li, G.; Teng, Y.; Wu, M.; et al. mRNA-based therapeutics: Powerful and versatile tools to combat diseases. Signal Transduct. Target. Ther. 2022, 7, 166. [Google Scholar] [CrossRef] [PubMed]
- Gong, Z.; Hu, W.; Zhou, C.; Guo, J.; Yang, L.; Wang, B. Recent advances and perspectives on the development of circular RNA cancer vaccines. NPJ Vaccines 2025, 10, 41. [Google Scholar] [CrossRef] [PubMed]
- Parhiz, H.; Atochina-Vasserman, E.N.; Weissman, D. mRNA-based therapeutics: Looking beyond COVID-19 vaccines. Lancet 2024, 403, 1192–1204. [Google Scholar] [CrossRef]
- Vavilis, T.; Stamoula, E.; Ainatzoglou, A.; Sachinidis, A.; Lamprinou, M.; Dardalas, I.; Vizirianakis, I.S. mRNA in the context of protein replacement therapy. Pharmaceutics 2023, 15, 166. [Google Scholar] [CrossRef]
- Lu, R.-M.; Hsu, H.-E.; Perez, S.J.L.P.; Kumari, M.; Chen, G.-H.; Hong, M.-H.; Lin, Y.-S.; Liu, C.-H.; Ko, S.-H.; Concio, C.A.P.; et al. Current landscape of mRNA technologies and delivery systems for new modality therapeutics. J. Biomed. Sci. 2024, 31, 89. [Google Scholar] [CrossRef]
- Enuka, Y.; Lauriola, M.; Feldman, M.E.; Sas-Chen, A.; Ulitsky, I.; Yarden, Y. Circular RNAs are long-lived and display only minimal early alterations in response to a growth factor. Nucleic Acids Res. 2016, 44, 1370–1383. [Google Scholar] [CrossRef]
- Suo, J.; Li, L.; Tan, W.; Yin, X.; Wang, J.; Shao, R.; Sun, S.; Guo, S.K.; Feng, J.; Gao, B.Q.; et al. Circular RNA-based protein replacement therapy mitigates osteoarthritis in male mice. Nat. Commun. 2025, 16, 8480. [Google Scholar] [CrossRef]
- Wesselhoeft, R.A.; Kowalski, P.S.; Anderson, D.G. Engineering circular RNA for potent and stable translation in eukaryotic cells. Nat. Commun. 2018, 9, 2629. [Google Scholar] [CrossRef]
- Holdt, L.M.; Kohlmaier, A.; Teupser, D. Circular RNAs as therapeutic agents and targets. Front. Physiol. 2018, 9, 1262. [Google Scholar] [CrossRef]
- Fitzgerald, K.D.; Semler, B.L. Bridging IRES elements in mRNAs to the eukaryotic translation apparatus. Biochim. Biophys. Acta 2009, 1789, 518–528. [Google Scholar] [CrossRef] [PubMed]
- Chen, R.; Wang, S.K.; Belk, J.A.; Amaya, L.; Li, Z.; Cardenas, A.; Abe, B.T.; Chen, C.-K.; Wender, P.A.; Chang, H.Y. Engineering Circular RNA for Enhanced Protein Production. Nat. Biotechnol. 2023, 41, 262–272. [Google Scholar] [CrossRef] [PubMed]
- Roberts, L.; Wieden, H.-J. Viruses, IRESs, and a universal translation initiation mechanism. Biotechnol. Genet. Eng. Rev. 2018, 34, 60–75. [Google Scholar] [CrossRef] [PubMed]
- Mizuguchi, H.; Xu, Z.; Ishii-Watabe, A.; Uchida, E.; Hayakawa, T. IRES-Dependent Second Gene Expression Is Significantly Lower than Cap-Dependent First Gene Expression in a Bicistronic Vector. Mol. Ther. 2000, 1, 376–382. [Google Scholar] [CrossRef]
- Martinez-Salas, E.; Francisco-Velilla, R.; Fernandez-Chamorro, J.; Embarek, A.M. Insights into Structural and Mechanistic Features of Viral IRES Elements. Front. Microbiol. 2018, 8, 2629. [Google Scholar] [CrossRef]
- Su, C.-I.; Chuang, Z.-S.; Shie, C.-T.; Wang, H.-I.; Kao, Y.-T.; Yu, C.-Y. A cis-acting ligase ribozyme generates circular RNA in vitro for ectopic protein functioning. Nat. Commun. 2024, 15, 6607. [Google Scholar] [CrossRef]
- Tong, M.; Palmer, N.; Dailamy, A.; Kumar, A.; Khaliq, H.; Han, S.; Finburgh, E.; Wing, M.; Hong, C.; Xiang, Y.; et al. Robust genome and cell engineering via in vitro and in situ circularized RNAs. Nat. Biomed. Eng. 2025, 9, 109–126. [Google Scholar] [CrossRef]
- Abdullah, S.W.; Wu, J.; Wang, X.; Guo, H.; Sun, S. Advances and Breakthroughs in IRES-Directed Translation and Replication of Picornaviruses. mBio 2023, 14, e0035823. [Google Scholar] [CrossRef]
- Sweeney, T.R.; Abaeva, I.S.; Pestova, T.V.; Hellen, C.U.T. The Mechanism of Translation Initiation on Type 1 Picornavirus IRESs. EMBO J. 2014, 33, 76–92. [Google Scholar] [CrossRef]
- Hunt, S.L.; Hsuan, J.J.; Totty, N.; Jackson, R.J. Unr, a Cellular Cytoplasmic RNA-Binding Protein with Five Cold-Shock Domains, Is Required for Internal Initiation of Translation of Human Rhinovirus RNA. Genes. Dev. 1999, 13, 437–448. [Google Scholar] [CrossRef]
- Verma, B.; Bhattacharyya, S.; Das, S. Polypyrimidine Tract-Binding Protein Interacts with Coxsackievirus B3 RNA and Influences Its Translation. J. Gen. Virol. 2010, 91, 1245–1255. [Google Scholar] [CrossRef] [PubMed]
- Chamond, N.; Deforges, J.; Ulryck, N.; Sargueil, B. 40S Recruitment in the Absence of eIF4G/4A by EMCV IRES Refines the Model for Translation Initiation on the Archetype of Type II IRESs. Nucleic Acids Res. 2014, 42, 10373–10384. [Google Scholar] [CrossRef] [PubMed]
- Yu, Y.; Abaeva, I.S.; Marintchev, A.; Pestova, T.V.; Hellen, C.U.T. Common Conformational Changes Induced in Type 2 Picornavirus IRESs by Cognate Trans-Acting Factors. Nucleic Acids Res. 2011, 39, 4851–4865. [Google Scholar] [CrossRef]
- Milo, R.; Jorgensen, P.; Moran, U.; Weber, G.; Springer, M. BioNumbers—The Database of Key Numbers in Molecular and Cell Biology. Nucleic Acids Res. 2010, 38, D750–D753. [Google Scholar] [CrossRef]
- Schwanhäusser, B.; Busse, D.; Li, N.; Dittmar, G.; Schuchhardt, J.; Wolf, J.; Chen, W.; Selbach, M. Global quantification of mammalian gene expression control. Nature 2011, 473, 337–342. [Google Scholar] [CrossRef] [PubMed]
- Geiger, T.; Wehner, A.; Schaab, C.; Cox, J.; Mann, M. Comparative Proteomic Analysis of Eleven Common Cell Lines Reveals Ubiquitous but Varying Expression of Most Proteins. Mol. Cell Proteom. 2012, 11, M111.014050. [Google Scholar] [CrossRef]
- Xu, C.; Pu, C.; Chen, R.; Wang, W.; Jiang, F.; Deng, C.; Zhai, D.; Chen, Y.; Hu, W.; Zhang, Y.; et al. circDesign Algorithm for Designing Synthetic Circular RNA. bioRxiv 2025. [Google Scholar] [CrossRef]
- Kaminski, A.; Jackson, R.J. The Polypyrimidine Tract Binding Protein (PTB) Requirement for Internal Initiation of Translation of Cardiovirus RNAs Is Conditional Rather than Absolute. RNA 1998, 4, 626–638. [Google Scholar] [CrossRef]
- Kaminski, A.; Howell, M.T.; Jackson, R.J. Initiation of Encephalomyocarditis Virus RNA Translation: The Authentic Initiation Site Is Not Selected by a Scanning Mechanism. EMBO J. 1990, 9, 3753–3759. [Google Scholar] [CrossRef]
- Davies, M.V.; Kaufman, R.J. The Sequence Context of the Initiation Codon in the Encephalomyocarditis Virus Leader Modulates Efficiency of Internal Translation Initiation. J. Virol. 1992, 66, 1924–1932. [Google Scholar] [CrossRef]
- Bochkov, Y.A.; Palmenberg, A.C. Translational Efficiency of EMCV IRES in Bicistronic Vectors Is Dependent upon IRES Sequence and Gene Location. Biotechniques 2006, 41, 283–288. [Google Scholar] [CrossRef]
- Cao, Y.; Liu, H.; Lu, S.S.; Jones, K.A.; Govind, A.P.; Jeyifous, O.; Simmons, C.Q.; Tabatabaei, N.; Green, W.N.; Holder, J.L.; et al. RNA-Based Translation Activators for Targeted Gene Upregulation. Nat. Commun. 2023, 14, 6827. [Google Scholar] [CrossRef]



| Plasmid | Relevant Characteristic | Source or Reference |
|---|---|---|
| pCircRNA-IRES-EV-A71-EGFP | single IRES, EV-A71, EGFP | PIE from [9]; IRES from [16]; sequence provided in Supplementary Table S1 |
| pCircRNA-IRES-EV-A71-nanoluc | single IRES, EV-A71, nanoluc | |
| pCircRNA-IRES-HRV-EGFP | single IRES, HRV, EGFP | HRV, iEV-B107, CVB3 IRESs from [12]; sequence provided in Supplementary Table S1 |
| pCircRNA-IRES-HRV-nanoluc | single IRES, HRV, nanoluc | |
| pCircRNA-IRES-iEV-B107-EGFP | single IRES, iEV-B107, EGFP | |
| pCircRNA-IRES-iEV-B107-nanoluc | single IRES, iEV-B107, nanoluc | |
| pCircRNA-IRES-CVB3-EGFP | single IRES, CVB3, EGFP | |
| pCircRNA-IRES-CVB3-nanoluc | single IRES, CVB3, nanoluc | |
| pCircRNA-IRES-EMCV-ΔATG11-EGFP | single IRES, EMCV-ΔATG11, EGFP | Laboratory stock; sequence provided in Supplementary Table S1 |
| pCircRNA-IRES-EMCV-ΔATG11-nanoluc | single IRES, EMCV-ΔATG11, nanoluc | |
| pCircRNA-IRES-EMCV-6A-EGFP | single IRES, EMCV-6A, EGFP | IRESs from [17]; sequence provided in Supplementary Table S1 |
| pCircRNA-IRES-EMCV-6A-nanoluc | single IRES, EMCV-6A, nanoluc | |
| pCircRNA-IRES-EMCV-7A-EGFP | single IRES, EMCV-7A, EGFP | |
| pCircRNA-IRES-EV-A71-EGFP-IRES-EV-A71 | dual IRES, EGFP flanked by EV-A71 | This work; full construct sequences provided in Supplementary Table S1 |
| pCircRNA-IRES-iEV-B107-EGFP-IRES-HRV | dual IRES, iEV-B107 preceded EGFP, HRV follows EGFP | |
| pCircRNA-IRES-HRV-EGFP-IRES-iEV-B107 | dual IRES, HRV precededs EGFP, iEV-B107 follows EGFP | |
| pCircRNA-IRES-EV-A71-EGFP-IRES-EMCV-ΔATG11 | dual IRES, EV-A71 precededs EGFP, EMCV-ΔATG11 follows EGFP | |
| pCircRNA-IRES-EMCV-ΔATG11-EGFP-IRES-CVB3 | dual IRES, EMCV-ΔATG11 precededs EGFP, CVB3 follows EGFP | |
| pCircRNA-IRES-EMCV-ΔATG11-EGFP-IRES-EV-A71 | dual IRES, EMCV-ΔATG11 precededs EGFP, EV-A71 follows EGFP | |
| pCircRNA-IRES-EMCV-ΔATG11-EGFP-IRES-EMCV-ΔATG11 | dual IRES, EGFP flanked by EMCV-ΔATG11 | |
| pCircRNA-IRES-EMCV-7A-EGFP-IRES-EMCV-7A | dual IRES, EMCV-7A precededs EGFP, EMCV-7A follows EGFP | |
| pCircRNA-IRES-EMCV-7A-EGFP-IRES-EMCV-ΔATG11 | dual IRES, EMCV-7A precededs EGFP, EMCV-ΔATG11 follows EGFP | |
| pCircRNA-IRES-EMCV-6A-EGFP-IRES-EMCV-6A | dual IRES, EMCV-6A precededs EGFP, EMCV-6A follows EGFP | |
| pCircRNA-IRES-EMCV-6A-EGFP-IRES-EMCV-ΔATG11 | dual IRES, EMCV-6A precededs EGFP, EMCV-ΔATG11 follows EGFP | |
| pCircRNA-IRES-EMCV-6A-EGFP-IRES-EMCV-7A | dual IRES, EMCV-6A precededs EGFP, EMCV-7A follows EGFP | |
| pCircRNA-IRES-EMCV-6A-EGFP-IRES-EMCV-ΔDI | dual IRES, EMCV-6A precededs EGFP, EMCV-ΔDI follows EGFP | |
| pCircRNA-IRES-EMCV-ΔATG11-nanoluc-IRES-EMCV-ΔATG11 | dual IRES, nanoluc flanked by EMCV-ΔATG11 | |
| pCircRNA-IRES-EMCV-6A-nanoluc-IRES-EMCV-7A | dual IRES, EMCV-6A precededs nanoluc, EMCV-7A follows nanoluc | |
| pCircRNA-IRES-EMCV-6A-nanoluc-IRES-EMCV-ΔATG11 | dual IRES, EMCV-6A precededs nanoluc, EMCV-ΔATG11 follows nanoluc | |
| pCircRNA-IRES-EMCV-6A-nanoluc-IRES-EMCV-6A | dual IRES, EMCV-6A precededs nanoluc, EMCV-6A follows nanoluc | |
| pCircRNA-IRES-EMCV-6A-nanoluc-IRES-EMCV-ΔDI | dual IRES, EMCV-6A precededs nanoluc, EMCV-ΔDI follows nanoluc |
| circRNA Construct | Replicate 1 | Replicate 2 | Replicate 3 | Mean ± SD (Fold/Mock) | CV (%) |
|---|---|---|---|---|---|
| EMCV-ΔATG11 | 31.28 | 36.96 | 40.78 | 36.34 ± 4.78 | 13.15 |
| EMCV-6A | 472.94 | 477.74 | 578.45 | 509.71 ± 59.58 | 11.69 |
| HRV | 250.35 | 229.84 | 277.37 | 252.52 ± 23.84 | 9.44 |
| A71 | 332.58 | 237.58 | 351.51 | 307.22 ± 61.05 | 19.87 |
| CVB3 | 438.24 | 520.54 | 568.53 | 509.11 ± 65.9 | 12.94 |
| iEV-B107 | 630.12 | 669.76 | 670.04 | 656.64 ± 22.97 | 3.50 |
| EMCV-6A+EMCV-6A | 950.90 | 1419.50 | 996.70 | 1122.37 ± 258.34 | 23.02 |
| dual EMCV-ΔATG11 | 325.82 | 306.52 | 329.74 | 320.69 ± 12.43 | 3.88 |
| EMCV 6A+EMCV-7A | 1205.59 | 1205.09 | 1581.90 | 1330.86 ± 217.41 | 16.34 |
| EMCV-6A+EMCV-ΔATG11 | 1350.80 | 951.35 | 1213.58 | 1171.91 ± 202.96 | 17.32 |
| EMCV-6A+EMCV-ΔDI | 1344.21 | 1488.20 | 1476.23 | 1436.21 ± 79.91 | 5.56 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.
Share and Cite
Sun, Y.; Zhang, Y.; Chen, W.; Chen, T.; Zhang, Y.; Zhang, S.; Lu, C. Enhancing Circular RNA Translation Efficiency Through Dual Internal Ribosome Entry Sites. Biology 2026, 15, 317. https://doi.org/10.3390/biology15040317
Sun Y, Zhang Y, Chen W, Chen T, Zhang Y, Zhang S, Lu C. Enhancing Circular RNA Translation Efficiency Through Dual Internal Ribosome Entry Sites. Biology. 2026; 15(4):317. https://doi.org/10.3390/biology15040317
Chicago/Turabian StyleSun, Yawen, Yimin Zhang, Weijie Chen, Ting Chen, Yunlong Zhang, Shanyu Zhang, and Changrui Lu. 2026. "Enhancing Circular RNA Translation Efficiency Through Dual Internal Ribosome Entry Sites" Biology 15, no. 4: 317. https://doi.org/10.3390/biology15040317
APA StyleSun, Y., Zhang, Y., Chen, W., Chen, T., Zhang, Y., Zhang, S., & Lu, C. (2026). Enhancing Circular RNA Translation Efficiency Through Dual Internal Ribosome Entry Sites. Biology, 15(4), 317. https://doi.org/10.3390/biology15040317
